{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:56:40Z","timestamp":1790686600106,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40122-026-00884-1","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:36:19Z","timestamp":1788183379000},"page":"1313-1343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Efficacy and Safety of Treatments for Chronic Peripheral Neuropathic Pain: A Systematic Review and Narrative Synthesis"],"prefix":"10.1007","volume":"15","author":[{"given":"Mari\u00eblle H.","family":"Eerdekens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Both","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1145-6444","authenticated-orcid":false,"given":"Rita L.","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"884_CR1","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1111\/pme.12845","volume":"16","author":"M Yang","year":"2015","unstructured":"Yang M, Qian C, Liu Y. Suboptimal treatment of diabetic peripheral neuropathic pain in the United States. Pain Med. 2015;16:2075\u201383.","journal-title":"Pain Med"},{"key":"884_CR2","first-page":"1990","volume":"25","author":"M Bussa","year":"2021","unstructured":"Bussa M, Mascaro A, Sbacchi E, Dourandish M, Rinaldi S. Understanding peripheral neuropathic pain in primary care: diagnosis and management. Eur Rev Med Pharmacol Sci. 2021;25:1990\u20136.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"884_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2023.1252442","volume":"16","author":"P Pacifico","year":"2023","unstructured":"Pacifico P, Coy-Dibley JS, Miller RJ, Menichella DM. Peripheral mechanisms of peripheral neuropathic pain. Front Mol Neurosci. 2023;16:1252442.","journal-title":"Front Mol Neurosci"},{"key":"884_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40122-020-00210-3","volume":"10","author":"A Liampas","year":"2021","unstructured":"Liampas A, Rekatsina M, Vadalouca A, Paladini A, Varrassi G, Zis P. Pharmacological management of painful peripheral neuropathies: a systematic review. Pain Ther. 2021;10:55\u201368.","journal-title":"Pain Ther"},{"key":"884_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3233\/NRE-208002","volume":"47","author":"D Murphy","year":"2020","unstructured":"Murphy D, Lester D, Clay Smither F, Balakhanlou E. Peripheral neuropathic pain. NeuroRehabil. 2020;47:265\u201383.","journal-title":"NeuroRehabil"},{"key":"884_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e38282","volume":"10","author":"JP Martins","year":"2024","unstructured":"Martins JP, Marson FAL. A narrative review of the complex panorama regarding chronic neuropathic pain mainly for the psychological issues. Heliyon. 2024;10:e38282.","journal-title":"Heliyon"},{"key":"884_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S1474-4422(25)00068-7","volume":"24","author":"N Soliman","year":"2025","unstructured":"Soliman N, Moisset X, Ferraro MC, de Andrade DC, Baron R, Belton J, et al. Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis. Lancet Neurol. 2025;24:413\u201328.","journal-title":"Lancet Neurol"},{"key":"884_CR8","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jpainsymman.2016.09.015","volume":"53","author":"C Sommer","year":"2017","unstructured":"Sommer C, Cruccu G. Topical treatment of peripheral neuropathic pain: applying the evidence. J Pain Symptom Manage. 2017;53:614\u201329.","journal-title":"J Pain Symptom Manage"},{"key":"884_CR9","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.pain.2012.12.022","volume":"154","author":"N Torrance","year":"2013","unstructured":"Torrance N, Ferguson JA, Afolabi E, Bennett MI, Serpell MG, Dunn KM, et al. Neuropathic pain in the community: more under-treated than refractory? Pain. 2013;154:690\u20139.","journal-title":"Pain"},{"key":"884_CR10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.bjae.2018.06.002","volume":"18","author":"BC Fitzmaurice","year":"2018","unstructured":"Fitzmaurice BC, Rayen ATA. Treatments for neuropathic pain: up-to-date evidence and recommendations. BJA Educ. 2018;18:277.","journal-title":"BJA Educ"},{"key":"884_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40265-020-01432-7","volume":"81","author":"KE Evoy","year":"2021","unstructured":"Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD. Abuse and misuse of pregabalin and gabapentin: a systematic review update. Drugs. 2021;81:125\u201356.","journal-title":"Drugs"},{"key":"884_CR12","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/bja\/aer260","volume":"107","author":"P Anand","year":"2011","unstructured":"Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107:490\u2013502.","journal-title":"Br J Anaesth"},{"key":"884_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.998904","volume":"13","author":"P Anand","year":"2022","unstructured":"Anand P, Privitera R, Donatien P, Fadavi H, Tesfaye S, Bravis V, et al. Reversing painful and non-painful diabetic neuropathy with the capsaicin 8% patch: clinical evidence for pain relief and restoration of function via nerve fiber regeneration. Front Neurol. 2022;13:998904.","journal-title":"Front Neurol"},{"key":"884_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108417","volume":"37","author":"S Tesfaye","year":"2023","unstructured":"Tesfaye S, Brill S, Eerdekens M, Labrador MM, Petersen G, de Rooij Peek A, et al. Diagnosis, management and impact of painful diabetic peripheral neuropathy: a patient survey in four European countries. J Diabetes Complicat. 2023;37:108417.","journal-title":"J Diabetes Complicat"},{"key":"884_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8336561","author":"N Hange","year":"2022","unstructured":"Hange N, Poudel S, Ozair S, Paul T, Nambakkam M, Shrestha R, et al. Managing chronic neuropathic pain: recent advances and new challenges. Neurol Res Int. 2022. https:\/\/doi.org\/10.1155\/2022\/8336561.","journal-title":"Neurol Res Int"},{"key":"884_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/j.pain.0000000000001365","volume":"160","author":"J Scholz","year":"2019","unstructured":"Scholz J, Finnerup NB, Attal N, Aziz Q, Baron R, Bennett MI, et al. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain. 2019;160:53\u20139.","journal-title":"Pain"},{"key":"884_CR17","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;372:n71.","journal-title":"BMJ"},{"key":"884_CR18","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162\u201373.","journal-title":"Lancet Neurol"},{"key":"884_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.","journal-title":"Syst Rev"},{"key":"884_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/03007995.2018.1558850","volume":"35","author":"M Lant\u00e9ri-Minet","year":"2019","unstructured":"Lant\u00e9ri-Minet M, Perrot S. QAPSA: post-marketing surveillance of capsaicin 8% patch for long-term use in patients with peripheral neuropathic pain in France. Curr Med Res Opin. 2019;35:417\u201326.","journal-title":"Curr Med Res Opin"},{"key":"884_CR21","first-page":"388","volume":"2","author":"AI Vinik","year":"2019","unstructured":"Vinik AI, Perrot S, Vinik E, Pazdera L, Stoker M, Snijder R, et al. Repeat treatment with capsaicin 8% patch (179 mg capsaicin cutaneous patch): Effects on pain, quality of life, and patient satisfaction in painful diabetic peripheral neuropathy: an open-label, randomized controlled clinical trial. J Curr Med Res Opin. 2019;2:388\u2013401.","journal-title":"J Curr Med Res Opin"},{"issue":"1","key":"884_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0752-7","volume":"16","author":"AI Vinik","year":"2016","unstructured":"Vinik AI, Perrot S, Vinik EJ, Pazdera L, Jacobs H, Stoker M, et al. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. BMC Neurol. 2016;16(1):251.","journal-title":"BMC Neurol"},{"key":"884_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020349","volume":"15","author":"F Bienfait","year":"2023","unstructured":"Bienfait F, Julienne A, Jubier-Hamon S, Seegers V, Delorme T, Jaoul V, et al. Evaluation of 8% capsaicin patches in chemotherapy-induced peripheral neuropathy: a retrospective study in a comprehensive cancer center. Cancers (Basel). 2023;15:349.","journal-title":"Cancers (Basel)"},{"key":"884_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2147\/JPR.S341378","volume":"15","author":"D Dupoiron","year":"2022","unstructured":"Dupoiron D, Jubier-Hamon S, Seegers V, Bienfait F, Pluchon YM, Lebrec N, et al. Peripheral neuropathic pain following breast cancer: effectiveness and tolerability of high-concentration capsaicin patch. J Pain Res. 2022;15:241\u201355.","journal-title":"J Pain Res"},{"key":"884_CR25","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/AJP.0000000000000057","volume":"30","author":"M Happich","year":"2014","unstructured":"Happich M, Schneider E, Boess FG, Wilhelm S, Schacht A, Birklein F, et al. Effectiveness of duloxetine compared with pregabalin and gabapentin in diabetic peripheral neuropathic pain: results from a German observational study. Clin J Pain. 2014;30:875\u201385.","journal-title":"Clin J Pain"},{"key":"884_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/2251-6581-13-62","volume":"13","author":"N Patel","year":"2014","unstructured":"Patel N, Mishra V, Patel P, Dikshit RK. A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy. J Diabetes Metab Disord. 2014;13:62.","journal-title":"J Diabetes Metab Disord"},{"key":"884_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.2040-1124.2011.00122.x","volume":"2","author":"J Satoh","year":"2011","unstructured":"Satoh J, Yagihashi S, Baba M, Suzuki M, Arakawa A, Yoshiyama T. Efficacy and safety evaluation of pregabalin treatment over 52 weeks in patients with diabetic neuropathic pain extended after a double-blind placebo-controlled trial. J Diabetes Investig. 2011;2:457\u201363.","journal-title":"J Diabetes Investig"},{"key":"884_CR28","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/j.1526-4637.2008.00423.x","volume":"9","author":"BR Stacey","year":"2008","unstructured":"Stacey BR, Dworkin RH, Murphy K, Sharma U, Emir B, Griesing T. Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial. Pain Med. 2008;9:1202\u20138.","journal-title":"Pain Med"},{"key":"884_CR29","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/j.1526-4637.2009.00796.x","volume":"11","author":"C Toth","year":"2010","unstructured":"Toth C. Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. Pain Med. 2010;11:456\u201365.","journal-title":"Pain Med"},{"key":"884_CR30","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1533-2500.2010.00427.x","volume":"11","author":"JA Bestard","year":"2011","unstructured":"Bestard JA, Toth CC. An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy. Pain Pract. 2011;11:353\u201368.","journal-title":"Pain Pract"},{"key":"884_CR31","first-page":"33","volume":"3","author":"W Eardley","year":"2010","unstructured":"Eardley W, Toth C. An open-label, non-randomized comparison of venlafaxine and gabapentin as monotherapy or adjuvant therapy in the management of neuropathic pain in patients with peripheral neuropathy. J Pain Res. 2010;3:33\u201349.","journal-title":"J Pain Res"},{"key":"884_CR32","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/AJP.0b013e31802fc14a","volume":"23","author":"S Giannopoulos","year":"2007","unstructured":"Giannopoulos S, Kosmidou M, Sarmas I, Markoula S, Pelidou SH, Lagos G, et al. Patient compliance with SSRIs and gabapentin in painful diabetic neuropathy. Clin J Pain. 2007;23:267\u20139.","journal-title":"Clin J Pain"},{"key":"884_CR33","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jdiacomp.2008.02.002","volume":"23","author":"HJ Ruessmann","year":"2009","unstructured":"Ruessmann HJ. Switching from pathogenetic treatment with alpha-lipoic acid to gabapentin and other analgesics in painful diabetic neuropathy: a real-world study in outpatients. J Diabetes Complicat. 2009;23:174\u20137.","journal-title":"J Diabetes Complicat"},{"key":"884_CR34","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.1526-4637.2006.00207.x","volume":"7","author":"J Raskin","year":"2006","unstructured":"Raskin J, Wang F, Pritchett YL, Goldstein DJ. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med. 2006;7:373\u201385.","journal-title":"Pain Med"},{"key":"884_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/jpm.2006.9.29","volume":"9","author":"J Raskin","year":"2006","unstructured":"Raskin J, Smith TR, Wong K, Pritchett YL, D\u2019Souza DN, Iyengar S, et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med. 2006;9:29\u201340.","journal-title":"J Palliat Med"},{"key":"884_CR36","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/dmrr.1000","volume":"25","author":"V Skljarevski","year":"2009","unstructured":"Skljarevski V, Desaiah D, Zhang Q, Chappell AS, Detke MJ, Gross JL, et al. Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain. Diabetes Metab Res Rev. 2009;25:623\u201331.","journal-title":"Diabetes Metab Res Rev"},{"key":"884_CR37","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.curtheres.2006.10.001","volume":"67","author":"JF Wernicke","year":"2006","unstructured":"Wernicke JF, Raskin J, Rosen A, Pritchett YL, D\u2019Souza DN, Iyengar S, et al. Duloxetine in the long-term management of diabetic peripheral neuropathic pain: an open-label, 52-week extension of a randomized controlled clinical trial. Curr Ther Res Clin Exp. 2006;67:283\u2013304.","journal-title":"Curr Ther Res Clin Exp"},{"key":"884_CR38","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1526-4637.2006.00258.x","volume":"8","author":"JF Wernicke","year":"2007","unstructured":"Wernicke JF, Wang F, Pritchett YL, Smith TR, Raskin J, D\u2019souza DN, et al. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med. 2007;8:503\u201313.","journal-title":"Pain Med"},{"key":"884_CR39","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/jdi.12361","volume":"7","author":"H Yasuda","year":"2016","unstructured":"Yasuda H, Hotta N, Kasuga M, Kashiwagi A, Kawamori R, Yamada T, et al. Efficacy and safety of 40 mg or 60 mg duloxetine in Japanese adults with diabetic neuropathic pain: results from a randomized, 52-week, open-label study. J Diabetes Investig. 2016;7:100\u20138.","journal-title":"J Diabetes Investig"},{"key":"884_CR40","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1097\/AJP.0000000000000473","volume":"33","author":"R G\u00e1lvez","year":"2017","unstructured":"G\u00e1lvez R, Navez ML, Moyle G, Maih\u00f6fner C, Stoker M, Ernault E, et al. Capsaicin 8% patch repeat treatment in nondiabetic peripheral neuropathic pain: a 52-week, open-label, single-arm, safety study. Clin J Pain. 2017;33:921\u201331.","journal-title":"Clin J Pain"},{"key":"884_CR41","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/papr.13345","volume":"24","author":"KU Kern","year":"2024","unstructured":"Kern KU, Quandel T, Theis S, Schubert T. Characteristics and outcomes of peripheral neuropathic pain patients with repeated applications of high-concentration capsaicin cutaneous patch: results of a retrospective chart review in Germany. Pain Pract. 2024;24:700\u20138.","journal-title":"Pain Pract"},{"key":"884_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-017-0836-z","volume":"17","author":"C Mankowski","year":"2017","unstructured":"Mankowski C, Poole CD, Ernault E, Thomas R, Berni E, Currie CJ, et al. Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study. BMC Neurol. 2017;17:80.","journal-title":"BMC Neurol"},{"key":"884_CR43","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2515\/therapie\/2015022","volume":"70","author":"M Schweitzer","year":"2015","unstructured":"Schweitzer M, Caillet JB, Paillet C, Baude C, Fagnoni P, Aulagner G, et al. Capsaicin cutaneous patch: a cost-consequences study in a French University Hospital. Therapie. 2015;70:359\u201368.","journal-title":"Therapie"},{"key":"884_CR44","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jpainsymman.2009.11.316","volume":"39","author":"DM Simpson","year":"2010","unstructured":"Simpson DM, Gazda S, Brown S, Webster LR, Lu SP, Tobias JK, et al. Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. J Pain Symptom Manage. 2010;39:1053\u201364.","journal-title":"J Pain Symptom Manage"},{"key":"884_CR45","first-page":"16","volume":"24","author":"E Treillet","year":"2023","unstructured":"Treillet E, Bitsch Tuet S, Maire A, Giet O, Serresse L. Gestion de la douleur induite et tol\u00e9rance de patch de capsa\u00efcine 8%: une analyse r\u00e9trospective de 1235 applications. Douleurs: \u00c9valuation - Diagnostic - Traitement. 2023;24:16\u201322.","journal-title":"Douleurs: \u00c9valuation - Diagnostic - Traitement"},{"key":"884_CR46","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40200-021-00741-2","volume":"20","author":"N Hussain","year":"2021","unstructured":"Hussain N, Said ASA, Javaid FA, Al Haddad AHI, Anwar M, Khan Z, et al. The efficacy and safety profile of capsaicin 8% patch versus 5% Lidocaine patch in patients with diabetic peripheral neuropathic pain: a randomized, placebo-controlled study of South Asian male patients. J Diabetes Metab Disord. 2021;20:271\u20138.","journal-title":"J Diabetes Metab Disord"},{"key":"884_CR47","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1002\/ejp.1180","volume":"22","author":"P Hansson","year":"2018","unstructured":"Hansson P, Jensen TS, Kvarstein G, Str\u00f6mberg M. Pain-relieving effectiveness, quality of life and tolerability of repeated capsaicin 8% patch treatment of peripheral neuropathic pain in Scandinavian clinical practice. Eur J Pain. 2018;22:941\u201350.","journal-title":"Eur J Pain"},{"key":"884_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1452099","volume":"14","author":"MP Lux","year":"2024","unstructured":"Lux MP, Fl\u00f6ther L, Fr\u00f6mter C, Rack B, Veselinovic K, Heine M, et al. Topical treatment of chemotherapy-induced peripheral neuropathy (CIPN) with high-concentration (179 mg) capsaicin patch in breast cancer patients\u2014results of the QUCIP study. Front Oncol. 2024;14:1452099.","journal-title":"Front Oncol"},{"key":"884_CR49","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1185\/03007990902901368","volume":"25","author":"G Hans","year":"2009","unstructured":"Hans G, Sabatowski R, Binder A, Boesl I, Rogers P, Baron R. Efficacy and tolerability of a 5% lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: results of a long-term study. Curr Med Res Opin. 2009;25:1295\u2013305.","journal-title":"Curr Med Res Opin"},{"key":"884_CR50","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/jdi.13178","volume":"11","author":"M Baba","year":"2020","unstructured":"Baba M, Matsui N, Kuroha M, Wasaki Y, Ohwada S. Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain. J Diabetes Investig. 2020;11:693\u20138.","journal-title":"J Diabetes Investig"},{"key":"884_CR51","doi-asserted-by":"publisher","first-page":"136","DOI":"10.22603\/ssrr.2022-0127","volume":"7","author":"T Yamanaka","year":"2022","unstructured":"Yamanaka T, Takeshita K, Mochizuki T, Inoue H, Akiyama T. Clinical outcomes of mirogabalin treatment for neuropathic pain due to spinal diseases in patients intolerant to continuous administration of pregabalin. Spine Surg Relat Res. 2022;7:136.","journal-title":"Spine Surg Relat Res"},{"key":"884_CR52","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.pain.2010.02.018","volume":"149","author":"RH Dworkin","year":"2010","unstructured":"Dworkin RH, Turk DC, Peirce-Sandner S, Baron R, Bellamy N, Burke LB, et al. Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain. 2010;149:177\u201393.","journal-title":"Pain"},{"key":"884_CR53","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","volume":"9","author":"RH Dworkin","year":"2008","unstructured":"Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105\u201321.","journal-title":"J Pain"},{"key":"884_CR54","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s12276-025-01409-0","volume":"57","author":"NJ Jayathilake","year":"2025","unstructured":"Jayathilake NJ, Phan TT, Kim J, Lee KP, Park JM. Modulating neuroplasticity for chronic pain relief: noninvasive neuromodulation as a promising approach. Exp Mol Med. 2025;57:501\u201314.","journal-title":"Exp Mol Med"},{"key":"884_CR55","unstructured":"FDA, CDER. Development of non-opioid analgesics for chronic pain: guidance for industry draft guidance [Internet]. [cited 2026 Apr 23]. https:\/\/www.fda.gov\/drugs\/guidance-compliance-regulatory-information\/guidances-drugs."},{"key":"884_CR56","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Guideline on the clinical development of medicinal products intended for the treatment of pain [Internet]. 2016 [cited 2026 Apr 23]. https:\/\/www.ema.europa.eu\/contact."},{"issue":"2","key":"884_CR57","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.bja.2025.10.047","volume":"136","author":"ME Koponen","year":"2026","unstructured":"Koponen ME, Senaratne DNS, H\u00e9bert HL, Smith BH, Colvin LA. Identifying predictors of neuropathic pain medication prescribing, adherence, and discontinuation: a systematic review and meta-analysis. Br J Anaesth. 2026;136(2):600\u201317.","journal-title":"Br J Anaesth"},{"key":"884_CR58","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2147\/JPR.S180792","volume":"12","author":"JM Keppel Hesselink","year":"2019","unstructured":"Keppel Hesselink JM, Kopsky DJ, Bhaskar AK. Ethical justification of single-blind and double-blind placebo-controlled response tests in neuropathic pain and N-of-1 treatment paradigm in clinical settings. J Pain Res. 2019;12:345\u201352.","journal-title":"J Pain Res"},{"key":"884_CR59","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.bja.2023.04.021","volume":"131","author":"N Attal","year":"2023","unstructured":"Attal N, Bouhassira D, Colvin L. Advances and challenges in neuropathic pain: a narrative review and future directions. Br J Anaesth. 2023;131:79\u201392.","journal-title":"Br J Anaesth"},{"key":"884_CR60","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN). SIGN 173: management of chronic pain (Part 1): a national clinical guideline [Internet]. Edinburgh: SIGN; 2025 [cited 2026 Apr 23]. https:\/\/www.sign.ac.uk\/media\/2389\/20251210-sign-chronic-pain-part-1.pdf."},{"key":"884_CR61","doi-asserted-by":"publisher","first-page":"845","DOI":"10.2217\/pmt-2022-0057","volume":"12","author":"R Baron","year":"2022","unstructured":"Baron R, Mick G, Serpell M. The relevance of real-world data for the evaluation of neuropathic pain treatments. Pain Manag. 2022;12:845\u201357.","journal-title":"Pain Manag"},{"key":"884_CR62","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2025-0094","volume":"14","author":"MS Olson","year":"2025","unstructured":"Olson MS, Freitas R. Are you implementation ready? An alternative patient and healthcare system-centered model for pharma. J Comp Eff Res. 2025;14:e250094.","journal-title":"J Comp Eff Res"},{"key":"884_CR63","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1080\/17512433.2016.1240029","volume":"9","author":"I Gilron","year":"2016","unstructured":"Gilron I. Methodological issues associated with clinical trials in neuropathic pain. Expert Rev Clin Pharmacol. 2016;9:1399\u2013402.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"884_CR64","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45:3415\u2013537.","journal-title":"Eur Heart J"},{"key":"884_CR65","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:159\u201382.","journal-title":"Ann Oncol"}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-026-00884-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-026-00884-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-026-00884-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:08:16Z","timestamp":1790683696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-026-00884-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["884"],"URL":"https:\/\/doi.org\/10.1007\/s40122-026-00884-1","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"26 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mari\u00eblle Eerdekens, Charlotte Both, and Rita Freitas are employees of Gr\u00fcnenthal GmbH, or its affiliates. Gr\u00fcnenthal holds the global rights to HCCP (Qutenza), one of the NeuPSIG-recommended treatments for PNP included in the scope of the SLR reported in this manuscript.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}